EN PL
 
EN PL
Bieżący numer
Archiwum
Online first
O czasopiśmie
Dla autorów
Książki i Konferencje
6/2017 vol. 55
Pobierz cytowanie
PRACA PRZEGLĄDOWA
Status of etoricoxib in the treatment of rheumatic diseases. Expert panel opinion
Brygida Kwiatkowska
,
 
Maria Majdan
,
 
Agnieszka Mastalerz-Migas
,
 
Maciej Niewada
,
 
Barbara Skrzydło-Radomańska
,
 
Artur Mamcarz
 
 
 
Więcej
Ukryj
 
Data nadesłania: 26-10-2017
 
 
Data akceptacji: 08-01-2018
 
 
Data publikacji online: 30-12-2017
 
 
Data publikacji: 31-12-2017
 
 
Reumatologia 2017;55(6):290-297
DOI: https://doi.org/10.5114/reum.2017.72626
 
 
Artykuł (PDF)
Referencje (51)
 
SŁOWA KLUCZOWE
etoricoxib
coxibs
cyclooxygenase COX-2
pain treatment
osteoarthritis
rheumatoid arthritis
ankylosing spondylitis
gout
 
DZIEDZINY
Nowe terapie w chorobach reumatycznych
 
STRESZCZENIE
Pain is one of the most disabling symptoms of rheumatoid diseases. Patients with pain secondary to osteoarthritis (OA), rheumatoid arthritis (RA), ankylosing spondylitis (AS) or gout require effective analgesic treatment, and the physician’s task is to select a drug that is best suited for an individual patient. The choice of pharmacotherapy should be based both on drug potency and clinical efficacy, and its safety profile, particularly in the elderly population, as the number of comorbidities (and hence the risk of treatment complications and drug interactions) rises with age. In cases involving a high risk of gastrointestinal complications or concerns about hepatotoxicity, with a low cardiovascular risk, the first-line nonsteroidal anti-inflammatory drugs to consider should be coxibs including etoricoxib.
REFERENCJE (51)
1.
Dallob A, Hawkey CJ, Greenberg H, et al. Characterization of etoricixib, a novel selective COX-2 inhibitor. J Clin Pharmacol 2003; 43: 573-585.
Google Scholar
 
 
2.
Leung GJ, Rainsford KD, Kean WF. Osteoarthritis of the hand I: aetiology and pathogenesis, risk factors, investigation and diagnosis. J Pharm Pharmacol 2013; 66: 339-346.
Google Scholar
 
 
3.
Bijsterbosch J, Meulenbelt I, Watt I, et al. Clustering of hand osteoarthritis progression and its relationship to progression of osteoarthritis at the knee. Ann Rheum Dis 2014; 73: 567-572.
Google Scholar
 
 
4.
Hochberg MC, Altman RD, April KT, et al. American College of Rheumatology 2012: Recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of hand, hip, and knee. Arthritis Care Res 2012; 64: 465-474.
Google Scholar
 
 
5.
Burmester G, Lanas A, Biasucci L, et al. The appropriate use of non-steroidal anti-inflammatory drugs in rheumatic disease: opinions of a multidisciplinary European expert panel. Ann Rheum Dis 2011; 70: 818-822.
Google Scholar
 
 
6.
Rahme E, Pettitt D, LeLorier J. Determinants and sequelae associated with utilization of acetaminophen versus traditional nonsteroidal antiinflammatory drugs in an elderly population. Arthritis Rheum 2002; 46: 3046-3054.
Google Scholar
 
 
7.
Van Laar M, Pergolizzi JV Jr, Mellinghoff HU, et al. Pain Treatment in Arthritis – Related Pain: Beyond NSAIDs. Open Rheumatol J 2012; 6: 320-330.
Google Scholar
 
 
8.
Puopolo A, Boice JA, Fidelholtz JL, et al. A randomized placebo-controlled trial comparing the efficacy of etoricoxib 30 mg and ibuprofen 2400 mg for the treatment of patients with osteoarthritis. Osteoarthritis and Cartilage 2007; 15: 1348-1356.
Google Scholar
 
 
9.
Bingham CO, Sebba AI, Rubin BR, et al. Efficacy and safety of etoricoxib 30 mg and celecoxib 200 mg in the treatment of osteoarthritis in two identically designed, randomized, placebo-controlled, non-inferiority studies. Rheumatology 2007; 46: 496-507.
Google Scholar
 
 
10.
Baraf HS, Fuentealba C, Greenwald M, et al. Gastrointestinal side effects of etoricoxib in patients with osteoarthritis: results of the Etoricoxib versus Diclofenac Sodium Gastrointestinal Tolerability and Effectiveness (EDGE) trial. J Rheumatol 2007; 34: 408-419.
Google Scholar
 
 
11.
Curtis SP, Bockow B, Fisher C, et al. Etoricoxib in the treatment of osteoarthritis over 52-weeks: a double-blind, active-comparator controlled trial [NCT00242489]. BMC Musculoskeletal Disorders 2005; 6: 58-68.
Google Scholar
 
 
12.
Stam W, Jansen J, Taylor S. Efficacy of etoricoxib, celecoxib, lumiracoxib, non-selective NSAIDs, and acetaminophen in osteoarthritis: a mixed treatment comparison. Open Rheumatol J 2012; 6: 6-20.
Google Scholar
 
 
13.
da Costa BR, Reichenbach S, Keller N, et al. Effectiveness of non-steroidal anti-inflammatory drugs for the treatment of pain in knee and hip osteoarthritis: a network meta-analysis. Lancet 2017; 390 (10090): e21-e33.
Google Scholar
 
 
14.
Smolen JS. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis 2017; 76: 960-977.
Google Scholar
 
 
15.
Collantes E, Curtis SP, Lee KW, et al. A multinational randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis [ISRCTN25142273]. BMC Family Practice 2002; 3: 10.
Google Scholar
 
 
16.
Kvien TK, Greenwald M, Peloso PM, et al. Do COX-2 inhibitors provide additional pain relief and anti-inflammatory effects in patients with rheumatoid arthritis who are on biological disease-modifying anti-rheumatic drugs and/or corticosteroids? Post-hoc analyses from a randomized clinical trial with etoricoxib. BMC Musculoskeletal Disorders 2015; 16: 26.
Google Scholar
 
 
17.
Bickham K, Kivitz AJ, Mehta A, et al. Evaluation of two doses of etoricoxib, a COX-2 selective non-steroidal anti-inflammatory drug (NSAID), in the treatment of Rheumatoid Arthritis in a double-blind, randomized controlled trial. BMC Musculoskletal Disorders 2016; 17: 331-342.
Google Scholar
 
 
18.
Krueger K, Lino L, Dore R, et al. Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients: results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE-II). Ann Rheum Dis 2008, 67: 315-322.
Google Scholar
 
 
19.
van der Heijde D, Ramiro S, Landewé R, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis 2017, 76: 978-991.
Google Scholar
 
 
20.
Wanders A, Heijde Dv, Landewé R, et al. Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum 2005, 52: 1756-1765.
Google Scholar
 
 
21.
Smolen JS, Braun J, Dougados M, et al. Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. Ann Rheum Dis 2014, 73: 6-16.
Google Scholar
 
 
22.
Tsai WC, Ou TT, Yen JH, et al. Long-term frequency use on non-steroidal anti-inflammatory drugs might protect patients with ankylosing spondylitis from cardiolvascular diseases: a nationwide case-control study. Plos One 2015; 10: e0126347.
Google Scholar
 
 
23.
Sieper J, Lenaerts J, Wollenhaupt J, et al. Maintenance of biologic-free remission with naproxen or no treatment in patients with early, active axial spondyloarthritis: resulta from a 6-month, randomised, open-label study, INFAST Part2. Ann Rheum Dis 2014, 73: 108-113.
Google Scholar
 
 
24.
van der Heijde D, Baraf HS, Ramos-Remus C, et al. Evaluation of the efficacy of etoricoxib in ankylosing spondylitis: Results of a fifty-two-week, randomized, controlled study. Arthritis Rheum 2005; 52: 1205-1215.
Google Scholar
 
 
25.
Wang R, Dasgupta A, Ward MM. Comparative efficacy of non-steroidal anti-inflammatory drugs in ankylosing spondylitis: a Bayesian network meta-analysis of clinical trials. Ann Rheum Dis 2016, 75: 1152-1160.
Google Scholar
 
 
26.
Gratacós J, Moreno Martínez-Losa M, Font P, et al. Etoricoxib in ankylosing spondylitis: is there a role for active patients refractory to traditional NSAIDs? Clin Exp Rheumatol 2016, 34: 94-99.
Google Scholar
 
 
27.
Bae JM, Choo JY, Kim KJ, et al. Association of inflammatory bowel disease with ankylosing spondylitis and rheumatoid arthritis: A nationwide population-based study. Modern Rheumatology 2017; 27: 435-440.
Google Scholar
 
 
28.
Ribaldone DG, Fagoonee S, Astegiano M, et al. Coxib safety in patients with inflammatory bowel diseases: a meta-analysis. Pain Physician 2015; 18: 599-607.
Google Scholar
 
 
29.
Sheth T, Pitchumoni CS, Das KM. Management of musculoskeletal manifestation in inflammatory bowel disease. Gastroenterol Res Pract 2015; 2015: 387891.
Google Scholar
 
 
30.
Jansen JP, Gaugris S, Choy EH, et al. Cost effectiveness of etoricoxib versus celecoxib and non-selective NSAIDS in the treatment of ankylosing spondylitis. Pharmacoeconomics 2010; 28: 323-344.
Google Scholar
 
 
31.
Khanna D, Fitzgerald JD, Khanna PP, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res 2012, 64: 1431-1446.
Google Scholar
 
 
32.
Khanna D, Khanna PP, Fitzgerald JD, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res 2012; 64: 1447-1461.
Google Scholar
 
 
33.
Richette P, Doherty M, Pascual E, et al. 2016 updated EULAR evidence-based recommendations for management of gout. Ann. Rheum. Dis 2017; 76: 29-42.
Google Scholar
 
 
34.
Kiltz U, Smolen J, Bardin T, et al. Treat-to-target (T2T) recommendations for gout. Ann Rheum Dis 2017, 76: 632-638.
Google Scholar
 
 
35.
Croom KF, Siddiqui MA. Etoricoxib. A review of its use in the symptomatic treatment of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis and acute gouty arthritis. Cochrane Database Syst Rev 2014; 9: CD010120.
Google Scholar
 
 
36.
Zhang S, Zhang Y, Liu P, et al. Efficacy and safety of etoricoxib compared with NSAIDs in acute gout: a systematic review and a meta-analysis. Clin Rheumatol 2016; 35: 151-158.
Google Scholar
 
 
37.
Schlansky B, Hwang JH. Prevention of nonsteroidal anti-inflammatory drug-induced gastropathy. J Gastroenterol 2009; 44 Suppl. 19: 44-52.
Google Scholar
 
 
38.
Huang JQ, Sridhar S, Hunt RH. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet 2002; 359:14-22.
Google Scholar
 
 
39.
Peura DA, Lanza FL, Gostout CJ, et al. The American College of Gastroenterology Bleeding Registry: preliminary findings. Am J Gastroenterol 1997; 92: 924-928.
Google Scholar
 
 
40.
Bhatt DL, Scheiman J, Abraham NS, et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol 2008; 52: 1502-1517.
Google Scholar
 
 
41.
Garcia Rodríguez LA, Hernández-Díaz S. The risk of upper gastrointestinal complications associated with nonsteroidal anti-inflammatory drugs, glucocorticoids, acetaminophen, and combinations of these agents. Arthritis Res 2001; 3: 98-101.
Google Scholar
 
 
42.
Sturkenboom MC, Burke TA, Dieleman JP, et al. Underutilization of preventive strategies in patients receiving NSAIDs. Rheumatology (Oxford) 2003; 42 (suppl 3): iii23-iii31.
Google Scholar
 
 
43.
Laine L, Curtis SP, Cryer B, et al. Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet 2007; 369: 465-473.
Google Scholar
 
 
44.
Hunt RH, Harper S, Watson DJ, et al. The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events. Am J Gastroenterol 2003; 98: 1725-1733.
Google Scholar
 
 
45.
Cannon CP, Curtis SP, FitzGerald GA, et al. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet 2006; 368: 1771-1781.
Google Scholar
 
 
46.
Farkouh ME, Greenberg JD, Jeger RV, et al. Cardiovascular outcomes in high risk patients with osteoarthritis treated with ibuprofen, naproxen or lumiracoxib. Ann Rheum Dis 2007; 66: 764-770.
Google Scholar
 
 
47.
Wilner KD, Rushing M, Walden C, et al. Celecoxib Does Not Affect the Antiplatelet Activity of Aspirin in Healthy Volunteers. J Clin Pharmacol 2002; 42: 1027-1030.
Google Scholar
 
 
48.
Trelle S, Reichenbach S, Wandel S, et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ 2011; 342: c7086.
Google Scholar
 
 
49.
Bhala N, Emberson J, Merhi A, et al.; Coxib and traditional NSAID Trialists’ (CNT) Collaboration. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet 2013, 382: 769-779.
Google Scholar
 
 
50.
van Walsem A, Pandhi S, Nixon RM, et al. Relative benefit-risk comparing diclofenac to other traditional non-steroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors in patients with osteoarthritis or rheumatoid arthritis: a network meta-analysis. Arthritis Res Ther 2015, 17: 66.
Google Scholar
 
 
51.
De Vecchis R, Baldi C, Di Biase G, et al. Cardiovascular risk associated with celecoxib or etoricoxib: a meta-analysis of randomized controlled trials which adopted comparison with placebo or naproxen. Minerva Cardioangiol 2014, 62: 437-448.
Google Scholar
 
 
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Udostępnij
Wyślij mailem
ARTYKUŁ POWIĄZANY
Key personal insights and changing needs of osteoarthritis patients: an international quantitative survey analysis
Comparison of treatment of severe rheumatoid arthritis patients with biological agents and JAK-STAT inhibitors. An extension study
Prevention of osteoarthritis
Miller-Fisher syndrome and monoclonal gammopathy in a patient with ankylosing spondylitis
An association between disease activity and obesity in patients with rheumatoid arthritis
Indeksy
 
Indeks słów kluczowych
Indeks dziedzin
Indeks autorów
eISSN:2084-9834
ISSN:0034-6233
Journals System - logo
© 2006-2024 Journal hosting platform by Bentus
Scroll to top